Skip to main navigation

Investor Relations

Home
Investors & Media
Contact Us
Careers

Overview
News / Events
Financial
- Annual Reports & Proxies
- Financial Results
Stock
SEC Filings
- All SEC Filings
Corporate Governance

Overview
News / Events
Financial
- Annual Reports & Proxies
- Financial Results
Stock
SEC Filings
- All SEC Filings
Corporate Governance

Press Coverage

Year

Oct 15, 2024

UNC School of Medicine, BioXcel Therapeutics Team Up to Tackle Acute Stress Disorder

Sep 12, 2024

New podcast: Are we close to an AI drug revolution?

Sep 09, 2024

BioXcel advances Alzheimer's agitation treatment

Jun 13, 2024

How AI Evolved Drug Redevelopment: Q&A with Dr. Friso Postma

Jun 10, 2024

The Pharma Phoenix: BioXcel Therapeutics Uses AI to Repurpose Shelved Drugs

Jun 01, 2024

Experimental Therapy Shows Promise in Pancreatic Cancer Clinical Trial

May 01, 2024

Inside BioXcel Therapeutics’ AI-driven drug re-innovation strategy

Apr 18, 2024

BioXcel planning pivotal trial of BXCL501 for Alzheimer’s agitation

Feb 02, 2024

Could a Georgetown Lab Finding Lead to New Treatment in Pancreatic Cancer?

Site - Investor Tools

Print Page

Tear Sheet

Email Alerts

RSS Feeds

Contacts

Search

About Us
Our Products
Our Pipeline
Our Science
Patients & Advocacy

Home
Investors & Media
Contact Us
Careers

Copyright © 2024 BioXcel Therapeutics, Inc. All Rights Reserved.

Privacy Policy
Disclaimer
Sitemap